Wednesday, September 14, 2011 10:02:17 AM
Notes from various ALNY conference calls and webcasts:
http://www.biotechduediligence.com/1/category/alnylam/1.html
Detailed summary of ALNY company and pipeline:
http://www.biotechduediligence.com/alny.html
http://www.biotechduediligence.com/1/category/alnylam/1.html
Detailed summary of ALNY company and pipeline:
http://www.biotechduediligence.com/alny.html
Any comments here may have previously been disseminated on Twitter @BioDueDiligence or at www.biotechduediligence.com
Recent ALNY News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/07/2026 08:21:18 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/07/2026 08:16:36 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/06/2026 09:01:20 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/06/2026 08:31:25 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/06/2026 08:30:28 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/06/2026 08:05:29 PM
- New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management • Business Wire • 03/30/2026 05:00:00 PM
- Alnylam teams up with Viz.ai and American Heart Association to advance ATTR-CM care • IH Market News • 03/24/2026 12:36:09 PM
- Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association • Business Wire • 03/24/2026 11:30:00 AM
- Alnylam to Webcast TTR Investor Webinar • Business Wire • 03/10/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 09:13:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 09:12:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 09:12:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 09:11:49 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/05/2026 09:04:27 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/05/2026 09:03:27 PM
- Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 12:31:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 12:30:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 12:30:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 12:29:11 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2026 10:17:57 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/03/2026 09:11:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/02/2026 09:10:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/02/2026 09:09:41 PM
